Rankings
▼
Calendar
IMUX Q4 2025 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena
IMUX
Immunic, Inc.
$135M
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$42,000
Operating Income
-$23M
Net Income
-$19M
EPS (Diluted)
$-0.04
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$19M
Free Cash Flow
-$19M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$24M
Total Liabilities
$31M
Stockholders' Equity
-$7M
Cash & Equivalents
$15M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$42,000
-$35,000
-20.0%
Operating Income
-$23M
-$26M
+9.0%
Net Income
-$19M
-$25M
+23.3%
← FY 2025
All Quarters